FATE - Here's Why Fate Therapeutics' Data Produced a 38% Jump in the Stock Price
In this video from Motley Fool Live recorded on Dec. 14, Bureau Chief of Healthcare and Cannabis Corinne Cardina and Fool.com contributor Brian Orelli discussed the boost in Fate Therapeutics ' (NASDAQ: FATE) stock price after the biotech presented data on its natural killer (NK) cell therapy.
The company didn't have much data at the American Society of Hematology (ASH) annual meeting. With the investment community focused on blood cancer drugs, Fate took the opportunity to release data for FT516, one of its NK-based treatments, before the conference.
For further details see:
Here's Why Fate Therapeutics' Data Produced a 38% Jump in the Stock Price